Can total testosterone testing miss tissue-level androgen deficiency?

Age-related physiological shifts can obscure androgen status in older men when evaluations rely solely on total testosterone measurements.

Clinical evidence

• Relying exclusively on serum total testosterone levels frequently misses tissue-level androgen deficiency in aging males.
• Sex Hormone-Binding Globulin (SHBG) increases by approximately 1% to 2% annually as men age. Consequently, total testosterone can appear normal even when free and bioavailable fractions are pathologically low.
• Multivariable panels integrating SHBG, calculated free testosterone, gonadotropins (LH/FSH), and metabolic status (such as insulin resistance and obesity) significantly improve diagnostic sensitivity for late-onset hypogonadism.
• Integrating environmental endocrine-disrupting chemical (EDC) exposures into clinical assessments is highly plausible, though it currently lacks standardized diagnostic guidelines and direct validation studies.

Mechanistic explanations

• Age-related elevations in SHBG directly decrease the circulating fractions of free and bioavailable testosterone.
• Because only unbound or weakly bound testosterone fractions can readily penetrate target cells to activate androgen receptors, their depletion leads directly to tissue-level deficiency.
• This intracellular androgen deficit impairs protein synthesis and cellular repair, resulting in a diminished anabolic reserve characterized by reduced muscle maintenance and recovery.

Bottom line

• Bottom line: Traditional total testosterone testing can mask a true tissue-level deficiency in older men due to rising SHBG levels; a comprehensive evaluation calculating free testosterone and assessing metabolic markers is essential for accurate clinical diagnosis.